Get started
Author

R.M. Layman

Observed names: R. Layman, R. M. Layman, RM Layman
Observed institutions: SHOWA Medical University, Cliniques Universitaires Saint-Luc, Mayo Clinic, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of Antwerp, University of California, San Francisco, Baylor College of Medicine, Genentech, University of Milan, University of Michigan, Cooper University Hospital, Massachusetts General Hospital, Centre Léon Bérard, Dana-Farber Cancer Institute, The Cancer Institute Hospital, National Cancer Centre Singapore, National Cancer Center Hospital East, Institut Paoli-Calmettes, Fondazione IRCCS Istituto Nazionale dei Tumori, Rutgers Cancer Institute, The Ohio State University, European Institute of Oncology
OpenAlex ID: A5004197652
LBA17 Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1
2025 · S.A. Hurvitz, R.M. Layman, et al. · Annals of Oncology · 11
PDF
Abstract GS3-06: Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (Ix) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)
2018 · HS Rugo, WT Barry, et al. · Cancer Research · 7
169P Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis
2022 · H.S. Rugo, A. Brufsky, et al. · Annals of Oncology · 4
Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices
2019 · R.M. Layman, X. Liu, et al. · Annals of Oncology · 3
Abstract P6-15-03: Phase Ib Trial of the Gamma Secretase Inhibitor (GSI), MK-0752 Followed by Docetaxel in Locally Advanced or Metastatic Breast Cancer
2010 · AF Schott, JC Chang, et al. · Cancer Research · 3
Abstract RF7-04: Gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+/HER2-/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trial
2026 · B. Pistilli, R. Layman, et al. · Clinical Cancer Research · 2
617TiP Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+HER− advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy
2025 · M. Oliveira, R.M. Layman, et al. · Annals of Oncology · 2
Abstract OT3-05-04: Phase II study of atezolizumab, cobimetinib, and eribulin in patients with recurrent or metastatic inflammatory breast cancer (IBC)
2019 · A Alexander, AN Marx, et al. · Cancer Research · 2
Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with progression on endocrine therapy (ET)
2019 · G Curigliano, S Cresta, et al. · Cancer Research · 2
EpCAM-negative cancer–associated circulating cells (CACS) in blood samples of women with triple-negative breast cancer (TNBC).
2011 · M. B. Lustberg, P. Balasubramanian, et al. · Journal of Clinical Oncology · 2
Abstract PS4-06-04: First-in-human Phase 1 study of BTX-9341, a CDK4/6 bifunctional degrader, as monotherapy and in combination with fulvestrant in patients with advanced and/or metastatic HR+/HER2- breast cancer - first emerging data
2026 · A. Patnaik, M. Block, et al. · Clinical Cancer Research · 1
Abstract PS1-10-09: Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients with ER+/HER2− metastatic breast cancer: results from phase 1 study to support the recommended phase 3 dose
2026 · P. M. LoRusso, T. Mukohara, et al. · Clinical Cancer Research · 1
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer
2026 · F. Lynce, C. Valenza, et al. · ESMO Open · 1
PDF
202P Early brain relapse in stage III inflammatory breast cancer occurs independent of molecular subtype
2025 · A. Nasrazadani, M. Kai, et al. · ESMO Open · 1
PDF
Abstract PS4-01-10: Characterizing CCR7 Gene Amplification and Protein Expression in Inflammatory and non-inflammatory Breast Cancer
2026 · S. Shivhare, C. Sanchez, et al. · Clinical Cancer Research
Abstract PS1-09-12: Trop2 expression and therapeutic opportunities in inflammatory breast cancer
2026 · S. Murray, A. Nasrazadani, et al. · Clinical Cancer Research
Abstract PS1-03-25: Incidence of hypersensitivity reactions in patients receiving trastuzumab biosimilars
2026 · E. M. Grannan, A. C. McGhie, et al. · Clinical Cancer Research
Abstract PD7-03: Circulating Immune Correlates of Pathological Response to Neoadjuvant Pembrolizumab plus Chemotherapy in High-Risk, Early-Stage Triple-Negative Breast Cancer
2026 · C. Yam, A. Radko, et al. · Clinical Cancer Research
Abstract PS1-07-23: Outcome After Locoregional Recurrences For Definitively Treated Non-Metastatic Inflammatory Breast Cancer
2026 · E. Onwubiko, M. Kai, et al. · Clinical Cancer Research
Abstract PS2-04-12: Real-world overall survival with palbociclib plus an aromatase inhibitor (AI) in patients with HR+/HER2− metastatic breast cancer (MBC) who are overweight/obese
2026 · A. Brufsky, N. Iyengar, et al. · Clinical Cancer Research
Abstract PS5-08-19: Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+HER2− advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy
2026 · K. M. Kalinsky, R. M. Layman, et al. · Clinical Cancer Research
Abstract PS1-11-10: Real-world progression-free survival 2 (rwPFS2) and tumor response with CDK4/6is + aromatase inhibitor (AI) in patients (pts) with HR+/HER2- metastatic breast cancer (MBC)
2026 · H. S. Rugo, A. Brufsky, et al. · Clinical Cancer Research
Abstract PS1-09-15: Prognostic Impact of BRCA Mutation Status on Outcomes with CDK4/6 Inhibitor Therapy in HR+/HER2- Metastatic Breast Cancer: A Real-World Cohort Study
2026 · A. Raghavendra, W. Qiao, et al. · Clinical Cancer Research
PS5-09-30: A phase 1/2 trial evaluating the safety, tolerability, and efficacy of the KAT6 inhibitor, PF-07248144, in combination with vepdegestrant in patients with ER+/HER2− locally advanced or metastatic breast cancer
2026 · F. Yan, T. Mukohara, et al. · Clinical Cancer Research
Abstract PD2-02: Stability of Estrogen receptor (ER), Progesterone receptor (PR), and Human epidermal growth factor receptor 2 (HER2) in Residual Invasive Tumor after Neoadjuvant Therapy in Inflammatory Breast Cancer
2026 · S. Krishnamurthy, R. S. Tidwell, et al. · Clinical Cancer Research
Works count: 32
Citation count: 42
H-index: 3
I10-index: 1
Year
Topic
Type